MUKILTEO, Wash., June 4, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that its subsidiary, Combimatrix Molecular Diagnostics (CMDX), has results from a multi-institute evaluation of its HemeScan(tm) test for CLL that were accepted for publication by the journal, Expert Opinions in Molecular Diagnostics (2008) 2(6): 1-10. The study, which was led by Dr. Shelly Gunn, Medical Director of CMDX, and which included collaborators from the prestigious M.D. Anderson Cancer Center, Texas, the Netherlands Cancer Institute, Amsterdam, and the University of Texas Health Science Center, San Antonio, evaluated over 170 patients with chronic lymphocytic leukemia (CLL) by the HemeScan test. The results of the study concluded that CMDX’s HemeScan test is a powerful and cost-effective tool for genome-wide risk assessment in the clinical evaluation of CLL.
